Effects of pravastatin, phytosterols, and combination therapy on lipid profile in HIV-infected patients: an open-labelled, randomized cross-over study

BMC Research Notes

Rattana Leelawattana¹  Noppadol Kietsiriroje¹ 

[1] Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkla 90110, Thailand

关键词: LDL-c;    Human immunodeficiency virus;    Phytosterols;    Pravastatin;   

Others  :  1231580
DOI  :  10.1186/s13104-015-1225-6

 received in 2015-02-09, accepted in 2015-06-11,  发布年份 2015

【 摘 要 】

Background

To determine the effects of 40 mg of pravastatin, 2 g of phytosterols, and combination therapy on lipid profiles and to compare the reduction of LDL cholesterol between combination therapy and monotherapy.

Methods

Thirty-six HIV-infected patients treated with ARVs who had high LDL cholesterol levels but no current usage of any lipid-lowering agents were enrolled into the open-labelled, randomized, cross-over study. All patients were assigned randomly into one of four intervention groups: (1) pravastatin 40 mg cross-over to the combination of pravastatin 40 mg and phytosterols 2 g (combination group), (2) the combination group cross-over to pravastatin 40 mg, (3) phytosterols 2 g cross-over to the combination group, and (4) the combination group cross-over to phytosterols 2 g. Each active treatment lasted 4 weeks with a wash-out period of 4 weeks.

Results

The baseline mean TC, TG, HDL-c, and LDL-c levels in 36 HIV patients were 248.09 ± 34.73, 172.36 ± 125.44, 54.92 ± 16.67, and 175.13 ± 29.00 mg/dl, respectively. Pravastatin, phytosterols, and combination therapy reduced TC and LDL-c but TG and HDL-c were not significantly different from the baselines. The mean LDL-c reductions in the pravastatin, phytosterols, and the combination groups were 28.76 ± 9.32, 9.12 ± 7.84, and 27.08 ± 15.58%, respectively. The LDL-c levels in the pravastatin and combination groups were reduced more than in the phytosterols group (p < 0.01). There was no difference in the LDL-c reduction between the combination and pravastatin monotherapy groups (−25.61 ± 10.43 vs. −28.12 ± 14.07%, p = 0.555).

Conclusion

Pravastatin had moderate potency on LDL-c lowering in HIV patients but could not bring LDL-c to goal. Adding phytosterols to pravastatin for a 4-week duration could not demonstrate any additional lipid-lowering effect

Trial registration: Thai Clinical Trial Registry: TCTR20150126002 date: January 23, 2015

【 授权许可】

   
2015 Kietsiriroje and Leelawattana.

【 图 表 】

Figure1.

Figure2.

Figure3.

Figure4.

Figure5.

【 参考文献 】

• [1]Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al.: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43(1):27-34.
• [2]Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF: Cardiovascular disease in HIV infection. Am Heart J 2006, 151(6):1147-1155.
• [3]Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003, 349(21):1993-2003.
• [4]Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d’Arminio Monforte A, et al.: Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS 2003, 17(8):1179-1193.
• [5]Mikhail NE: LIPID abnormalities in patients infected with human immunodeficiency virus. Endocr Pract 2008, 14(4):492-500.
• [6]Singh S, Willig JH, Mugavero MJ, Crane PK, Harrington RD, Knopp RH, et al.: Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis 2011, 52(3):387-395.
• [7]Martinez E, Leyes P, Ros E: Effectiveness of lipid-lowering therapy in HIV patients. Curr Opin HIV AIDS 2008, 3(3):240-246.
• [8]Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37(5):613-627.
• [9]Scholle JM, Baker WL, Talati R, Coleman CI: The effect of adding plant sterols or stanols to statin therapy in hypercholesterolemic patients: systematic review and meta-analysis. J Am Coll Nutr 2009, 28(5):517-524.
• [10]Thompson GR: Role of plant sterols in lipid lowering—a safety issue. QJM 2011, 104(8):729-730.
• [11]Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al.: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32(14):1769-1818.
• [12]Third Report of the National Cholesterol Education Program: (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 2002, 106(25):3143-3421.
• [13]Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al.: American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary. Endocr Pract 2012, 18(2):269-293.
• [14]Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003, 92(2):152-160.
• [15]Hurlimann D, Chenevard R, Ruschitzka F, Flepp M, Enseleit F, Bechir M, et al.: Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart 2006, 92(1):110-112.
• [16]Stein JH, Merwood MA, Bellehumeur JL, Aeschlimann SE, Korcarz CE, Underbakke GL, et al.: Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004, 147(4):E18.
• [17]Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F: Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008, 6(6):572-578.
• [18]Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, et al.: Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 2010, 24(1):77-83.
• [19]Kriengsinyos W, Sumriddetchkajorn K, Yamborisut U: Reduction of LDL-cholesterol in mildly hypercholesterolemic Thais with plant stanol ester-fortified soy milk. J Med Assoc Thai 2011, 94(11):1327-1336.
• [20]Simons LA: Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol 2002, 90(7):737-740.
• [21]Cater NB, Garcia-Garcia AB, Vega GL, Grundy SM: Responsiveness of plasma lipids and lipoproteins to plant stanol esters. Am J Cardiol 2005, 96(1A):23D-28D.
• [22]Gylling H, Miettinen TA: Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res 1996, 37(8):1776-1785.
• [23]Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R: Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003, 78(8):965-978.
• [24]Abumweis SS, Barake R, Jones PJ (2008) Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res. 52. doi:10.3402/fnr.v52i0.1811
• [25]Thongtang N, Lin J, Schaefer EJ, Lowe RS, Tomassini JE, Shah AK, et al.: Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients. Atherosclerosis 2012, 225(2):388-396.
• [26]Qi Y, Liu J, Ma C, Wang W, Liu X, Wang M, et al.: Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease. J Lipid Res 2013, 54(11):3189-3197.